Co-stimulatory and Co-inhibitory Pathways in Cancer Immunotherapy

Overview

Journal Adv Cancer Res

Publisher Elsevier

Specialty Oncology

Date 2019 Jun 17

PMID 31202358

Citations 45

Authors

Rachel E ONeill

Xuefang Cao

Affiliations

Soon will be listed here.

Abstract

Cancer remains the leading cause of death worldwide. Traditional treatments such as surgery, radiation, and chemotherapy have had limited efficacy, especially with late stage cancers. Cancer immunotherapy and targeted therapy have revolutionized how cancer is treated, especially in patients with late stage disease. In 2013 cancer immunotherapy was named the breakthrough of the year, partially due to the established efficacy of blockade of CTLA-4 and PD-1, both T cell co-inhibitory molecules involved in tumor-induced immunosuppression. Though early trials promised success, toxicity and tolerance to immunotherapy have hindered long-term successes. Optimizing the use of co-stimulatory and co-inhibitory pathways has the potential to increase the effectiveness of T cell-mediated antitumor immune response, leading to increased efficacy of cancer immunotherapy. This review will address major T cell co-stimulatory and co-inhibitory pathways and the role they play in regulating immune responses during cancer development and treatment.

Citing Articles

Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis.

He B, Zhao R, Zhang B, Pan H, Liu J, Huang L J Clin Invest. 2025; 135(5).

PMID: 40026246 PMC: 11870743. DOI: 10.1172/JCI186291.

Therapeutic Applications of Programmed Death Ligand 1 Inhibitors in Small Cell Lung Cancer.

Nabipur L, Mouawad M, Venketaraman V Biomedicines. 2025; 13(2).

PMID: 40002814 PMC: 11852381. DOI: 10.3390/biomedicines13020401.

CD28 Superfamily Costimulatory Molecules in Chronic Pain: Focus on Immunomodulation.

Shi Q, Luo Y, Xiang Q, Kang X, Feng Z Mol Neurobiol. 2025; .

PMID: 39956885 DOI: 10.1007/s12035-025-04746-3.

Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances.

Kulbay M, Tuli N, Mazza M, Jaffer A, Juntipwong S, Marcotte E Biomedicines. 2025; 13(1).

PMID: 39857692 PMC: 11762644. DOI: 10.3390/biomedicines13010108.

Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.

Cesano A, Augustin R, Barrea L, Bedognetti D, Bruno T, Carturan A J Immunother Cancer. 2025; 13(1).

PMID: 39824527 PMC: 11749597. DOI: 10.1136/jitc-2024-008876.

References

Shilling R, Clay B, Tesciuba A, Berry E, Lu T, Moore T . CD28 and ICOS play complementary non-overlapping roles in the development of Th2 immunity in vivo. Cell Immunol. 2009; 259(2):177-84. PMC: 2748173. DOI: 10.1016/j.cellimm.2009.06.013. View

van Kooten C, Banchereau J . Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997; 9(3):330-7. DOI: 10.1016/s0952-7915(97)80078-7. View

Sakuishi K, Jayaraman P, Behar S, Anderson A, Kuchroo V . Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011; 32(8):345-9. PMC: 3164311. DOI: 10.1016/j.it.2011.05.003. View

Wikenheiser D, Ghosh D, Kennedy B, Stumhofer J . The Costimulatory Molecule ICOS Regulates Host Th1 and Follicular Th Cell Differentiation in Response to Plasmodium chabaudi chabaudi AS Infection. J Immunol. 2015; 196(2):778-91. PMC: 4705592. DOI: 10.4049/jimmunol.1403206. View

Bettini M, Szymczak-Workman A, Forbes K, Castellaw A, Selby M, Pan X . Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol. 2011; 187(7):3493-8. PMC: 3178660. DOI: 10.4049/jimmunol.1100714. View

Stuber E, Strober W, Neurath M . Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med. 1996; 183(2):693-8. PMC: 2192468. DOI: 10.1084/jem.183.2.693. View

Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K . Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood. 2000; 95(7):2434-9. View

Chen L, Ashe S, Brady W, Hellstrom I, Hellstrom K, Ledbetter J . Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992; 71(7):1093-102. DOI: 10.1016/s0092-8674(05)80059-5. View

Saoulli K, Lee S, Cannons J, Yeh W, Santana A, Goldstein M . CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med. 1998; 187(11):1849-62. PMC: 2212301. DOI: 10.1084/jem.187.11.1849. View

10.

Ndhlovu L, Lopez-Verges S, Barbour J, Jones R, Jha A, Long B . Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012; 119(16):3734-43. PMC: 3335380. DOI: 10.1182/blood-2011-11-392951. View

11.

Leigh N, ONeill R, Du W, Chen C, Qiu J, Ashwell J . Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. J Immunol. 2017; 199(1):336-347. PMC: 5503479. DOI: 10.4049/jimmunol.1502181. View

12.

Peperzak V, Veraar E, Keller A, Xiao Y, Borst J . The Pim kinase pathway contributes to survival signaling in primed CD8+ T cells upon CD27 costimulation. J Immunol. 2010; 185(11):6670-8. DOI: 10.4049/jimmunol.1000159. View

13.

Cooke P, James N, Ganesan R, Wallace M, Burton A, Young L . CD40 expression in bladder cancer. J Pathol. 1999; 188(1):38-43. DOI: 10.1002/(SICI)1096-9896(199905)188:1<38::AID-PATH315>3.0.CO;2-B. View

14.

Gramaglia I, Jember A, Pippig S, Weinberg A, Killeen N, Croft M . The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 2000; 165(6):3043-50. DOI: 10.4049/jimmunol.165.6.3043. View

15.

Triebel F, JITSUKAWA S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E . LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990; 171(5):1393-405. PMC: 2187904. DOI: 10.1084/jem.171.5.1393. View

16.

Huang Y, Zhu C, Kondo Y, Anderson A, Gandhi A, Russell A . CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2014; 517(7534):386-90. PMC: 4297519. DOI: 10.1038/nature13848. View

17.

Baum P, Gayle 3rd R, Ramsdell F, Srinivasan S, Sorensen R, Watson M . Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 1994; 13(17):3992-4001. PMC: 395319. DOI: 10.1002/j.1460-2075.1994.tb06715.x. View

18.

Calderhead D, Buhlmann J, van den Eertwegh A, Claassen E, Noelle R, Fell H . Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol. 1993; 151(10):5261-71. View

19.

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View

20.

Snell L, McPherson A, Lin G, Sakaguchi S, Pandolfi P, Riccardi C . CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol. 2010; 185(12):7223-34. DOI: 10.4049/jimmunol.1001912. View